• Explore /
  • Poster
  • / A phase 1b/2, open label, dose-escalation study of margetuximab (M) in combination with pembrolizumab (P) in patients with relapsed/refractory advanced HER2+ gastroesophageal (GEJ) junction or gastric (G) cancer.

A phase 1b/2, open label, dose-escalation study of margetuximab (M) in combination with pembrolizumab (P) in patients with relapsed/refractory advanced HER2+ gastroesophageal (GEJ) junction or gastric (G) cancer.

Abstract Poster

Authors

Daniel Catenacci

Daniel V.T. Catenacci

The University of Chicago, Chicago, IL

Daniel V.T. Catenacci , Sunnie S. Kim , Philip Jordan Gold , Philip Agop Philip , Peter C. Enzinger , Joe Coffie , Emmett V. Schmidt , Malcolm Baldwin , Jeffrey L. Nordstrom , Ezio Bonvini , Jon M. Wigginton , Howard S. Hochster , Crystal Shereen Denlinger , Hope Elizabeth Uronis , Johanna C. Bendell , Ronan Joseph Kelly , Jan Kenneth Davidson-Moncada , Albert C. Lockhart

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach

Track

Cancers of the Esophagus and Stomach

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT02689284

Citation

J Clin Oncol 35, 2017 (suppl 4S; abstract TPS219)

DOI

10.1200/JCO.2017.35.4_suppl.TPS219

Abstract #

TPS219

Poster Bd #

O1

Abstract Disclosures

Similar Posters

First Author: Daniel V.T. Catenacci

First Author: Daniel V.T. Catenacci

First Author: Daniel V.T. Catenacci

First Author: Timothy Jay Price